IMMUNOTAC
Silverback Therapeutics, Inc.
Mark For: IMMUNOTAC® trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88108634 |
| Registration Number | 6200968 |
| Mark Literal Elements | IMMUNOTAC |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK |
| Register | PRINCIPAL |
| Current Location | PUBLICATION AND ISSUE SECTION 2020-10-13 |
| Basis | 1(a) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | Yes |
| Intent To Use | No |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Joi A. White |
| Attorney Docket Number | T-4153/1 US |
| Law Office Assigned | L90 |
| Employee Name | STIGLITZ, SUSAN R |
Timeline
| 2018-09-07 | Application Filed |
| 2018-12-19 | Status: Live/Pending |
| 2018-12-28 | Location: GENERIC WEB UPDATE |
| 2019-01-02 | Transaction Date |
| 2020-02-25 | Published |
| 2020-06-26 | Date of First Use |
| 2020-06-26 | Date of Use In Commerce |
| 2020-10-13 | Location: PUBLICATION AND ISSUE SECTION |
| 2020-11-17 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
| 2020-11-17 | Trademark Registered |
Trademark Parties (Applicants & Owners)
| Party: |  Silverback Therapeutics, Inc. |
| Address | 500 Fairview Avenue North, Suite 600 Seattle, WASHINGTON UNITED STATES 98109 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
 Drawing | JPEG | 2018-09-07 |
 TEAS RF New Application | MULTI | 2018-09-07 |
| XSearch Search Summary | XML | 2018-12-18 |
| Offc Action Outgoing | XML | 2018-12-19 |
| Administrative Response | XML | 2018-12-28 |
| Response to Office Action | MULTI | 2019-06-18 |
| Amendment and Mail Process Complete | MULTI | 2019-06-20 |
| Offc Action Outgoing | XML | 2019-07-08 |
| Notation to File | XML | 2019-12-18 |
| TEAS Request Reconsideration after FOA | XML | 2020-01-08 |
| Amendment and Mail Process Complete | MULTI | 2020-01-10 |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2020-01-22 |
| Notice of Publication | XML | 2020-02-05 |
| Notification Of Notice of Publication | XML | 2020-02-05 |
| OG Publication Confirmation | APPLICATION/XML | 2020-02-25 |
| Notice of Allowance | XML | 2020-04-21 |
| Specimen | JPEG | 2020-09-08 |
| Statement of Use | MULTI | 2020-09-08 |
| ITU Unit Action | APPLICATION/XML,IMAGE/JPEG | 2020-09-23 |
| Notice of Acceptance of Statement of Use | XML | 2020-10-14 |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2020-10-14 |
| Registration Certificate | 2020-11-17 |
Attorney of Record
Good, Services, and Codes
IC 005. US 006 018 044 046 051 052. G & S: Systemically delivered, locally active immune modulatory conjugates in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceuticals and pharmaceutical preparations of systemically delivered, locally active immune modulatory conjugates for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; engineered immunomodulatory therapeutics in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases. FIRST USE: 20200626. FIRST USE IN COMMERCE: 20200626
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Systemically delivered, locally active immune modulatory conjugates for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceuticals and pharmaceutical preparations of systemically delivered, locally active immune modulatory conjugates for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; engineered immunomodulatory therapeutics for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases |
| GS0051 | Systemically delivered, locally active immune modulatory conjugates in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceuticals and pharmaceutical preparations of systemically delivered, locally active immune modulatory conjugates for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; engineered immunomodulatory therapeutics in the nature of pharmaceuticals, including biopharmaceuticals, pharmaceutical preparations, including biopharmaceutical preparations, agents, namely, biopharmaceutical and pharmaceutical preparations and substances, and medicines for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| REGISTERED-PRINCIPAL REGISTER | 2020-11-17 | |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2020-10-14 | |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2020-10-13 | |
| STATEMENT OF USE PROCESSING COMPLETE | 2020-09-22 | 66530 |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2020-09-22 | 66530 |
| USE AMENDMENT FILED | 2020-09-08 | 66530 |
| TEAS STATEMENT OF USE RECEIVED | 2020-09-08 | |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2020-04-21 | |
| PUBLISHED FOR OPPOSITION | 2020-02-25 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-02-25 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-02-05 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-01-21 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-01-09 | 88889 |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2020-01-08 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-01-08 | 88889 |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-07-08 | |
| FINAL REFUSAL WRITTEN | 2019-07-08 | 76487 |
| FINAL REFUSAL E-MAILED | 2019-07-08 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-06-19 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-06-18 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-06-18 | 88889 |
| LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | 2018-12-31 | 76487 |
| LETTER OF PROTEST EVIDENCE FORWARDED | 2018-12-28 | |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-12-19 | 6325 |
| NON-FINAL ACTION WRITTEN | 2018-12-19 | 76487 |
| NON-FINAL ACTION E-MAILED | 2018-12-19 | 6325 |
| ASSIGNED TO EXAMINER | 2018-12-18 | 76487 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-09-15 | |
| NEW APPLICATION ENTERED IN TRAM | 2018-09-11 |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 IMMUNOTAC 88108651 not registered Live/Pending |
Silverback Therapeutics, Inc. 2018-09-07 |
 IMMUNOTAC 88108634 not registered Live/Pending |
Silverback Therapeutics, Inc. 2018-09-07 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 